Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2018 08:00 ET | Source: Paratek Pharmaceuticals

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, March 30, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
March 28, 2018 08:00 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Present at the H.C. Wainwright Annual Global Life Sciences Conference

BOSTON, March 28, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that President, Chief Operating Officer and Chief Medical Officer, Evan Loh, MD will present at...
March 16, 2018 08:00 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference

BOSTON, March 16, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that President, Chief Operating Officer and Chief Medical Officer, Evan Loh, MD, will present...
March 02, 2018 08:00 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Present at the 38th Annual Cowen & Co. Health Care Conference

BOSTON, March 02, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that President, Chief Operating Officer and Chief Medical Officer, Evan Loh, MD, will present...
March 01, 2018 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, March 01, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
March 01, 2018 07:00 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Remains on Track for Commercial Launch by First Quarter 2019

Completed submission of NDAs for oral and intravenous omadacycline for the treatment of pneumonia and skin infectionsExpanded medical affairs and payer account management teams in readiness for...
February 15, 2018 08:00 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018

BOSTON, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
February 05, 2018 07:30 ET | Source: Paratek Pharmaceuticals

Paratek Completes Submission of New Drug Applications to U.S. Food and Drug Administration for Oral and Intravenous Omadacycline for Pneumonia and Skin Infections

BOSTON, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that on February 2, 2018, it completed the submission of two New Drug Applications (NDAs) to the...
February 01, 2018 16:01 ET | Source: Paratek Pharmaceuticals

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
January 31, 2018 08:00 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Present at LEERINK Partners 7th Annual Global Healthcare Conference

BOSTON, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), announced today that its President, Chief Operating Officer and Chief Medical Officer, Evan Loh, MD and Chief...